09/18/2024
3:38 PM | Novartis (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/17/2024
4:08 PM | Novartis (Filer)
Novartis Capital CORP (Filer)
| Form 424B5 | |
09/17/2024
1:05 PM | Novartis (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/16/2024
4:12 PM | Novartis (Subject)
| Form FWP | |
09/16/2024
7:44 AM | Novartis (Filer)
Novartis Capital CORP (Filer)
| Form 424B5 | |
09/16/2024
7:12 AM | Novartis (Filer)
Novartis Capital CORP (Filer)
| Form F-3ASR | |
08/15/2024
3:30 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC 13D/A | |
|
08/13/2024
3:31 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC TO-T/A | |
08/12/2024
2:30 PM | Kowalski Robert William (Reporting)
Novartis (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/07/2024
7:12 PM | Novartis (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/07/2024
3:30 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC TO-T/A | |
08/02/2024
3:30 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC TO-T/A | |
08/01/2024
3:30 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC TO-T/A | |
07/31/2024
3:30 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC TO-T/A | |
07/30/2024
3:30 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC TO-T/A | |
07/29/2024
3:30 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC TO-T/A | |
07/25/2024
3:30 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC TO-T/A | |
07/18/2024
3:30 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC TO-T/A | |
07/18/2024
5:09 AM | Novartis (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/11/2024
3:30 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC TO-T/A | |
07/05/2024
5:02 AM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC TO-T | |
06/21/2024
3:30 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC 13D/A | |
06/20/2024
2:38 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC TO-C | |
06/17/2024
3:30 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC 13D/A | |
06/10/2024
3:30 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC 13D/A | |
06/04/2024
3:30 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC TO-T/A | |
05/31/2024
5:00 AM | Novartis (Filer)
| Form SD
Specialized Disclosure Report | |
05/22/2024
11:42 AM | Gal Aharon (Reporting)
Novartis (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/16/2024
3:31 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC TO-T/A | |
05/07/2024
3:45 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC TO-T/A | |
05/06/2024
3:30 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC TO-T/A | |
05/02/2024
3:31 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC TO-T/A | |
04/25/2024
3:30 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC TO-T/A | |
04/23/2024
5:06 AM | Novartis (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/18/2024
3:31 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC TO-T/A | |
04/18/2024
1:33 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC 13D | |
04/17/2024
3:30 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC TO-T/A | |
04/16/2024
4:07 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC TO-T/A | |
04/15/2024
2:44 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC TO-T/A | |
04/11/2024
5:01 AM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC TO-T | |
02/15/2024
3:15 PM | Novartis (Filer)
| Form S-8 POS | |
Who are Nvidia’s New Silent Partners? (Ad) Nvidia recently became just the third $2 trillion company.
But Nvidia can’t do everything by itself. I call these Nvidia’s “Silent Partners.” |
02/06/2024
3:52 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC TO-C | |
02/05/2024
4:06 PM | MorphoSys AG (Subject)
MorphoSys AG (Subject)
Novartis (Filed by)
| Form SC TO-C | |
02/02/2024
1:18 PM | BlackRock Inc. (Filed by)
Novartis (Subject)
| Form SC 13G/A | |
01/31/2024
6:43 AM | Novartis (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/31/2024
6:43 AM | Novartis (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/31/2024
6:44 AM | Novartis (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/31/2024
6:44 AM | Novartis (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/31/2024
6:38 AM | Novartis (Filer)
| Form 20-F
Registration statement / Annual report / Transition report | |
01/31/2024
6:42 AM | Novartis (Filer)
| Form IRANNOTICE | |
01/08/2024
5:13 AM | Novartis (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/11/2023
5:05 AM | Novartis (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/05/2023
7:19 PM | Novartis (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/28/2023
5:10 AM | Novartis (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/30/2023
5:05 AM | Novartis (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/24/2023
5:33 AM | Novartis (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/04/2023
5:57 AM | Novartis (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/02/2023
5:05 AM | Novartis (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
